Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 583

Showing 1-25 of 583 citing articles:

Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis
Naoki Kondo, Takeshi Kuroda, Daisuke Kobayashi
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 10922-10922
Open Access | Times Cited: 309
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich, April W. Armstrong, Richard Langley, et al.
The Lancet (2019) Vol. 394, Iss. 10201, pp. 831-839
Closed Access | Times Cited: 297
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B. Warren, Mark Lebwohl, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 142-152
Open Access | Times Cited: 273
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Atul Deodhar, P. J. Mease, Iain B. McInnes, et al.
Arthritis Research & Therapy (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 258
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Claudia Schinocca, Chiara Rizzo, Serena Fasano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 241
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim Papp, Andrew Blauvelt, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 487-498
Closed Access | Times Cited: 213
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 212
Neutrophils in Psoriasis
Chih-Chao Chiang, Wei-Jen Cheng, Michal Korinek, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 211
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B. Gordon, Peter Foley, James G. Krueger, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 475-486
Closed Access | Times Cited: 202
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
Kinga Tóth, Dorottya Ádám, Tamás Bı́ró, et al.
Molecules (2019) Vol. 24, Iss. 5, pp. 918-918
Open Access | Times Cited: 176
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
Richard B. Warren, Andrew Blauvelt, Yves Poulin, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 1, pp. 50-59
Open Access | Times Cited: 155
Skin Barrier Dysregulation in Psoriasis
Andreas Orsmond, Lara Bereza-Malcolm, Tom Lynch, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10841-10841
Open Access | Times Cited: 126
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 118
IL-25 (IL-17E) in epithelial immunology and pathophysiology
Julia Borowczyk, Maria S. Shutova, Nicolò Costantino Brembilla, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 1, pp. 40-52
Open Access | Times Cited: 108
Current Concepts of Psoriasis Immunopathogenesis
Marijana Vičić, Marija Kaštelan, Ines Brajac, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11574-11574
Open Access | Times Cited: 104
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F. Merola, Robert Landewé, Iain B. McInnes, et al.
The Lancet (2022) Vol. 401, Iss. 10370, pp. 38-48
Open Access | Times Cited: 103
Exploring the Role of Staphylococcus aureus in Inflammatory Diseases
Huanquan Chen, Junyan Zhang, Ying He, et al.
Toxins (2022) Vol. 14, Iss. 7, pp. 464-464
Open Access | Times Cited: 94
Gut–Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis
Angel Yun-Kuan Thye, Yi-Rou Bah, Jodi Woan‐Fei Law, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1037-1037
Open Access | Times Cited: 88
Targeting strategies for bone diseases: signaling pathways and clinical studies
Hao Xu, Wentao Wang, Xin Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review
Lucas Fornari Laurindo, Gabriel Magno de Carvalho, Bárbara de Oliveira Zanuso, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 229-229
Open Access | Times Cited: 50
Disease modification in inflammatory skin disorders: opportunities and challenges
Thomas Bieber
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 662-680
Closed Access | Times Cited: 43
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C. Coates, Robert Landewé, Iain B. McInnes, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003855-e003855
Open Access | Times Cited: 17
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
Lisha Li, Jiaye Lu, Jun Liu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 15
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J. Mease, Philip Helliwell, Kasper Fjellhaugen Hjuler, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 185-193
Open Access | Times Cited: 106
Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation
Bin Zhang, Ruenn Chai Lai, Wei Kian Sim, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 720-720
Open Access | Times Cited: 92
Page 1 - Next Page

Scroll to top